Corpus 1,284 assessed · 1,185 scored · 647 reproduced ≥75 · 173 flagged ·∅ 73.9/100

Publications 2 Datasets 392.5k Experiments 5.8k

Explore

Filters: 2024 ✕ Oncology ✕ other ✕ clear all

2 matching publication(s)

Publication	Journal	Year	Score	Verdict
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104). PMID 38897205	Cell Rep Med	2024	72	L1 72/100
Decoding the tumor microenvironment and molecular mechanism: unraveling cervical cancer subpopulations and prognostic signatures through scRNA-Seq and bulk RNA- PMID 38482016	Front Immunol	2024	80	L1 80/100

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).

PMID 38897205 · Cell Rep Med · 2024

L1 72/100

Decoding the tumor microenvironment and molecular mechanism: unraveling cervical cancer subpopulations and prognostic signatures through scRNA-Seq and bulk RNA-

PMID 38482016 · Front Immunol · 2024

L1 80/100